基因表达特征用于指导ER+/HER2-早期乳腺癌的初始治疗
Sara Marín-Liébana1,2, Paula Llor1, Lucía Serrano-García1
1Medical Oncology Department, Hospital Arnau de Vilanova, 46015 Valencia, Spain.
Cancers
|May 14, 2025
概括
基因表达试验在预测早期乳腺癌 (EBC) 的新辅助治疗反应方面表现有希望. 这些测试可能有助于个性化治疗决策,特别是对于雌激素受体阳性/人表皮生长因子受体2-阴性 (ER+/HER2-) 乳腺癌.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 翻译医学是一种翻译医学.
背景情况:
- 新辅助系统治疗是大型三阴性 (TNBC) 和HER2+乳腺癌的标准.
- 由于反应率较低,其在ER+/HER2-乳腺癌中的益处受到辩论.
- 准确预测新辅助药治疗反应仍然是一个挑战.
研究的目的:
- 审查基因表达特征,以预测乳腺癌中新辅助治疗反应.
- 评估这些签名在核心针活检中的实用性.
- 检查新辅助治疗和正在进行的试验后签名的变化.
主要方法:
- 对常见的基因表达特征 (MammaPrint,BluePrint,型Dx,PAM50,BCI,EndoPredict) 发表的数据的审查.
- 对预测新辅助化疗 (CT) 或内分泌疗法 (ET) 反应的特征能力的分析.
- 对核心针活检和后期治疗的签名使用的评估.
主要成果:
- 基因表达试验越来越多地用于指导ER+/HER2-EBC的辅助治疗.
- 它们对新辅助治疗反应的预测价值正在调查中.
- 需要进一步的研究来优化它们在新辅助剂环境中的使用.
结论:
- 基因表达特征具有个性化新辅助疗法选择的潜力.
- 核心针活检应用和治疗后分析是关键的研究领域.
- 目前正在进行的试验将进一步确定这些特征在新辅助乳腺癌治疗中的作用.
更多相关视频
08:29Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
53
10:36Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
Published on: March 17, 2016
10.3K
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:38Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K